Fast Five Quiz: HIV Pre-exposure Prophylaxis: Selecting Appropriate Candidates

Jason F. Okulicz, MD


June 09, 2022

Human immunodeficiency virus (HIV) continues to be a major public health crisis worldwide despite the decline in incidence; however, a "sizable" number of cases still occur each year. At the end of 2020, the World Health Organization estimated that 37.7 million individuals were living with HIV. The life expectancy of individuals living with HIV has increased dramatically with the development of HIV therapies, shifting the focus of management to prevention. In 2012 the US Food and Drug Administration (FDA) approved the first pre-exposure prophylaxis (PrEP) for the prevention of HIV and it is now available across 76 countries. A second PrEP treatment was FDA approved in 2019, and a third (a long-acting injectable agent) in 2021. International guidelines have been issued to assist with selecting appropriate candidates for HIV PrEP. Although there is no cure for HIV, effective prevention is possible.

How much do you know about selecting candidates for HIV PrEP? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.